Pfizer Report Results of Etrasimod in P-III (ELEVATE UC 52) Study for the Treatment of Ulcerative Colitis
Shots:
- Everest licensing partner Pfizer reported results from the 2nd P-III (ELEVATE UC 52) study evaluate etrasimod (2mg, qd) vs PBO in a ratio (2:1) in 433 patients with active UC who had prior failed or were intolerant to one conventional, biologic, or JAK inhibitor therapy
- The results showed that patients achieved an improvements in the co-primary EPs & all key 2EPs of clinical remission @12 & 52wks. The safety profile was consistent with the previous studies including the P-II (OASIS) trial
- The company will use these results along with (ELEVATE UC 12) & long-term extension from these 2 trials (ELEVATE UC OLE) for future regulatory filings with an expected initiation in 2022
Ref: PR Newswire | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
